Pathophysiology of ANCA-associated vasculitides;Physiopathologie des vascularites ANCA-positives

Presse Medicale

Volumn 41, Issue 10, 2012, Pages 996-1003

  Mouthon, Luc ^a,b,c,d   Millet, Arnaud ^a,b,c   Régent, Alexis ^a,b,c   Pederzoli Ribeil, Magali ^a,b,c   Witko Sarsat, Véronique ^a,b,c  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB;

ACUTE PHASE RESPONSE; ANCA ASSOCIATED VASCULITIS; B LYMPHOCYTE; CELL MEMBRANE; CELL SURFACE; CELLULAR IMMUNITY; CHRONIC PHASE RESPONSE; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DENDRITIC CELL; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME LOCALIZATION; FIBROBLAST; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MICROSCOPIC POLYANGIITIS; MONOCYTE; NEUTROPHIL; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; RESPIRATORY SYSTEM; SHORT SURVEY; TH17 CELL; TH2 CELL; WEGENER GRANULOMATOSIS;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; EOSINOPHILS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MODELS, BIOLOGICAL;

EID: 84866348589     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.07.007     Document Type: Short Survey

References (44)

1. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37(2):187-192.
2. van der Woude F.J., Rasmussen N., Lobatto S., Wiik A., Permin H., van Es L.A., et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985, 1(8426):425-429.
3. Jennette J.C. Nomenclature and classification of vasculitis: lessons learned from granulomatosis with polyangiitis (Wegener's granulomatosis). Clin Exp Immunol 2011, 164(Suppl. 1):7-10.
4. Guilpain P., Chanseaud Y., Tamby M.C., Mahr A., Servettaz A., Guillevin L., et al. [Pathogenesis of primary systemic vasculitides (I): ANCA-positive vasculitides]. Presse Med 2005, 34(14):1013-1022.
5. Guillevin L., Durand-Gasselin B., Cevallos R., Gayraud M., Lhote F., Callard P., et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999, 42(3):421-430.
6. Sinico R.A., Di Toma L., Maggiore U., Bottero P., Radice A., Tosoni C., et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005, 52(9):2926-2935.
7. Sablé-Fourtassou R., Cohen P., Mahr A., Pagnoux P., Mouthon L., Jayne D., et al. Antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Ann Intern Med 2005, 143:632-638.
8. Witko-Sarsat V., Lesavre P., Lopez S., Bessou G., Hieblot C., Prum B., et al. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 1999, 10(6):1224-1233.
9. Kantari C., Pederzoli-Ribeil M., Amir-Moazami O., Gausson-Dorey V., Moura I.C., Lecomte M.C., et al. Proteinase 3, the Wegener autoantigen, is externalized during neutrophil apoptosis: evidence for a functional association with phospholipid scramblase 1 and interference with macrophage phagocytosis. Blood 2007.
10. Witko-Sarsat V., Reuter N., Mouthon L. Interaction of proteinase 3 with its associated partners: implications in the pathogenesis of Wegener's granulomatosis. Curr Opin Rheumatol 2010, 22(1):1-7.
11. Pendergraft W.F., Preston G.A., Shah R.R., Tropsha A., Carter C.W., Jennette J.C., et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004, 10(1):72-79.
12. Tadema H., Kallenberg C.G., Stegeman C.A., Heeringa P. Reactivity against complementary proteinase-3 is not increased in patients with PR3-ANCA-associated vasculitis. PLoS One 2011, 6(3):e17972.
13. Kain R., Exner M., Brandes R., Ziebermayr R., Cunningham D., Alderson C.A., et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008, 14(10):1088-1096.
14. Kain R., Tadema H., McKinney E.F., Benharkou A., Brandes R., Peschel A., et al. High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol 2011, 23(3):556-566.
15. Roth A.J., Brown M.C., Smith R.N., Badhwar A.K., Parente O., Chung H., et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol 2011, 23(3):545-555.
16. Tadema H., Abdulahad W.H., Lepse N., Stegeman C.A., Kallenberg C.G., Heeringa P. Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology (Oxford) 2011, 50(4):689-696.
17. Tadema H., Abdulahad W.H., Stegeman C.A., Kallenberg C.G., Heeringa P. Increased expression of Toll-like receptors by monocytes and natural killer cells in ANCA-associated vasculitis. PLoS One 2011, 6(9):e24315.
18. Jennette J.C., Falk R.J. Antineutrophil cytoplasmic autoantibodies associated diseases: a review. Am J Kidney Dis 1990, 15(6):517-529.
19. Reumaux D., Vossebeld P.J., Roos D., Verhoeven A.J. Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood 1995, 86(8):3189-3195.
20. Guilpain P., Servettaz A., Goulvestre C., Barrieu S., Borderie D., Chereau C., et al. Pathogenic effects of anti-myeloperoxidase antibodies in patients with microscopic polyangiitis. Arthritis Rheum 2007, 56(7):2455-2463.
21. Jennette J.C., Xiao H., Heeringa P., Liu Z., Hu P., Aratani Y., et al. Induction of pauci-immune necrotizing and crescentic glomerulonephritis (NCGN) by intravenous administration of anti-myeloperoxidase (anti-MPO- antibodies to recombinase activating gene-2 deficient (Rag-2 -/-) mice. Cleve Clin J Med 2002, 69(Suppl. 2):SII-13. abstract 2-090.
22. Xiao H., Heeringa P., Hu P., Liu Z., Zhao M., Aratani Y., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110(7):955-963.
23. Schreiber A., Xiao H., Jennette J.C., Schneider W., Luft F.C., Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009, 20(2):289-298.
24. Bansal P.J., Tobin M.C. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004, 93(4):398-401.
25. Primo V.C., Marusic S., Franklin C.C., Goldmann W.H., Achaval C.G., Smith R.N., et al. Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis. Clin Exp Immunol 2010, 159(3):327-337.
26. Little M.A., Al-Ani B., Ren S., Al-Nuaimi H., Leite M., Alpers C.E., et al. Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One 2012, 7(1):e28626.
27. Kessenbrock K., Krumbholz M., Schonermarck U., Back W., Gross W.L., Werb Z., et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009, 15(6):623-625.
28. Menegazzi R., Decleva E., Dri P. Killing by neutrophil extracellular traps: fact or folklore?. Blood 2012, 119(5):1214-1216.
29. Nauseef W.M. Editorial: Nyet to NETs? A pause for healthy skepticism. J Leukoc Biol 2012, 91(3):353-355.
30. van Rossum A.P., Rarok A.A., Huitema M.G., Fassina G., Limburg P.C., Kallenberg C.G. Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti-PR3 antibodies. J Leukoc Biol 2004, 76(6):1162-1170.
31. Woywodt A., Streiber F., de Groot K., Regelsberger H., Haller H., Haubitz M. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003, 361(9353):206-210.
32. Voswinkel J., Mueller A., Kraemer J.A., Lamprecht P., Herlyn K., Holl-Ulrich K., et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006, 65(7):859-864.
33. Abdulahad W.H., Lamprecht P., Kallenberg C.G. T-helper cells as new players in ANCA-associated vasculitides. Arthritis Res Ther 2011, 13(4):236.
34. Csernok E., Ai M., Gross W.L., Wicklein D., Petersen A., Lindner B., et al. Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood 2006, 107(11):4440-4448.
35. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363(3):221-232.
36. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363(3):211-220.
37. Stegeman C.A., Tervaert J.W., Sluiter W.J., Manson W.L., de Jong P.E., Kallenberg C.G. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis [see comments]. Ann Intern Med 1994, 120(1):12-17.
38. Knight A., Sandin S., Askling J. Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease. Arthritis Rheum 2008, 58(1):302-307.
39. Willcocks L.C., Lyons P.A., Rees A.J., Smith K.G. The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis. Arthritis Res Ther 2010, 12(1):202.
40. Knight A., Sandin S., Askling J. Increased risk of autoimmune disease in families with Wegener's granulomatosis. J Rheumatol 2010, 37(12):2553-2558.
41. Jagiello P., Gencik M., Arning L., Wieczorek S., Kunstmann E., Csernok E., et al. New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet 2004, 114(5):468-477.
42. Chen M., Kallenberg C.G. ANCA-associated vasculitides-advances in pathogenesis and treatment. Nat Rev Rheumatol 2010, 6(11):653-664.
43. Kelley J.M., Monach P.A., Ji C., Zhou Y., Wu J., Tanaka S., et al. IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc Natl Acad Sci U S A 2011, 108(51):20736-20741.
44. Lyons P.A., Rayner T.F., Trivedi S., Holle J.U., Watts R.A., Jayne D.R., et al. Genetically distinct subsets within ANCA-Associated Vasculitis. N Engl J Med. 2012, 367(3):214-223.